Abstract
There is increasing evidence that certain probiotic strains can be useful in improving human health. The use of probiotics has received attention as a natural way of restoring bodys normal microbiota, and an alternative and inexpensive way of preventing or treating infectious diseases without side effects. The best-documented clinical application of probiotics comes from trials on the treatment of gastrointestinal infections, mainly infectious diarrhoea. The enhancement of local as well as systemic immune responses by probiotics also offers new opportunities for probiotics in preventing infections at distal mucosal surfaces, such as those in the oral cavity, respiratory and urogenital tracts. The underlying mechanisms of probiotics are still unclear, but may include strengthening of the non-immunological gut barrier, interference with pathogen adhesion and growth inhibition, and the enhancement of the local mucosal immune system in the gut, as well as of the systemic immune response.
Keywords: Probiotics, Lactobacillus, Bifidobacterium, gastrointestinal, oral, respiratory, urogenital, infection
Current Pharmaceutical Design
Title: Probiotics in Intestinal and Non-Intestinal Infectious Diseases – Clinical Evidence
Volume: 14 Issue: 14
Author(s): K. Hatakka and M. Saxelin
Affiliation:
Keywords: Probiotics, Lactobacillus, Bifidobacterium, gastrointestinal, oral, respiratory, urogenital, infection
Abstract: There is increasing evidence that certain probiotic strains can be useful in improving human health. The use of probiotics has received attention as a natural way of restoring bodys normal microbiota, and an alternative and inexpensive way of preventing or treating infectious diseases without side effects. The best-documented clinical application of probiotics comes from trials on the treatment of gastrointestinal infections, mainly infectious diarrhoea. The enhancement of local as well as systemic immune responses by probiotics also offers new opportunities for probiotics in preventing infections at distal mucosal surfaces, such as those in the oral cavity, respiratory and urogenital tracts. The underlying mechanisms of probiotics are still unclear, but may include strengthening of the non-immunological gut barrier, interference with pathogen adhesion and growth inhibition, and the enhancement of the local mucosal immune system in the gut, as well as of the systemic immune response.
Export Options
About this article
Cite this article as:
Hatakka K. and Saxelin M., Probiotics in Intestinal and Non-Intestinal Infectious Diseases – Clinical Evidence, Current Pharmaceutical Design 2008; 14 (14) . https://dx.doi.org/10.2174/138161208784480162
DOI https://dx.doi.org/10.2174/138161208784480162 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Use of Phages for the Removal of Infectious Biofilms
Current Pharmaceutical Biotechnology <i>Propionibacterium acnes</i> in the Pathogenesis and Immunotherapy of Acne Vulgaris
Current Drug Metabolism Virtual Screening for the Development of New Effective Compounds Against Staphylococcus aureus
Current Medicinal Chemistry Inside the Pan-genome - Methods and Software Overview
Current Genomics Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets Methadone and the Heart: What the Clinician Needs to Know
Current Drug Abuse Reviews Severe Community-Acquired Pneumonia (CAP) due to Atypical Pathogens
Current Respiratory Medicine Reviews Cardiovascular Disease in Juvenile Idiopathic Arthritis
Current Vascular Pharmacology Novel Approaches to Control Biofilm Infections
Current Medicinal Chemistry Endocarditis Due to Salmonella Enterica Subsp. Arizonae in a Patient with Sickle Cell Disease: A Case Report and Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Molecular Imaging of Vascular Thrombosis
Current Molecular Imaging (Discontinued) Preparation and Characterization of Chitosan-Based Spray-Dried Microparticles for the Delivery of Clindamycin Phosphate to Periodontal Pockets
Current Drug Delivery Contrast Media in Cardiovascular Magnetic Resonance
Current Pharmaceutical Design Methods to Measure Target Site Penetration of Antibiotics in Critically Ill Patients
Current Clinical Pharmacology New Developments in Therapeutic Agents for Legionnaires Disease
Anti-Infective Agents in Medicinal Chemistry Research Progress in Live Attenuated Brucella Vaccine Development
Current Pharmaceutical Biotechnology The Importance of Guidelines in the Development and Application of Probiotics
Current Pharmaceutical Design Amphotericin B LIPOMER for Enhanced Splenic Delivery
Drug Delivery Letters Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders